Trial Profile
A Single- and Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of LY3009104 in Healthy Chinese Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 16 Jan 2020
Price :
$35
*
At a glance
- Drugs Baricitinib (Primary)
- Indications Atopic dermatitis; Diabetic nephropathies; Psoriasis; Rheumatoid arthritis
- Focus Adverse reactions
- Sponsors Eli Lilly and Company
- 06 Jun 2019 According to an Eli Lilly media release, data from this trial will be presented at the upcoming Annual European Congress of Rheumatology (EULAR 2019) in Madrid from June 12-15, 2019.
- 25 Aug 2016 Status changed from recruiting to completed.
- 15 Jun 2016 Planned End Date changed from 1 Oct 2016 to 1 Sep 2016.